Drug intelligence / Profile preview

MYJ1633-BCS

Development stage: Unknown
Lead developer: IMMUNISBIO
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

MYJ1633-BCS is an autologous natural killer (NK) cell therapy developed by Immunisbio for the treatment of HER2-positive breast cancer. The therapy involves the ex vivo expansion and activation of a patient's own NK cells, which are then re-infused to target and eliminate tumor cells expressing the Human Epidermal Growth Factor Receptor 2 (HER2). MYJ1633-BCS has been evaluated in Phase 1/2a clinical trials, often in combination with other therapeutic agents, to enhance anti-tumor efficacy in patients with advanced or metastatic HER2-positive breast cancer.

Other names: MYJ1633-BCSMYJ-1633-BCSMYJ 1633-BCS

Beyond the preview

Go deeper on MYJ1633-BCS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MYJ1633-BCS.

Explore the full profile